Ovarian Cancer | Oncology Today with Dr Neil Love: Role of PARP Inhibition in Ovarian Cancer

Featuring perspectives from Dr Thomas Herzog, including the following topics: Impact of PARP inhibitors (PARPi) on the care of patients with ovarian cancer (0:00) Clarifying the recent withdrawal of PARPi for treatment of recurrent or refractory ovarian cancer (4:13) Sequential use of PARPi for patients with advanced ovarian cancer (16:56) Case: Woman in her late 60s with BRCA wild type ovarian cancer (20:06) Case: Woman in her early 50s with somatic BRCA-positive high-grade serous ovarian cancer (39:22) Case: Woman in her mid 60s with BRCA wild type and homologous recombination-deficient endometroid ovarian cancer (44:02) CME information and select publications

Om Podcasten

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.